Coeptis Therapeutics Stock In The News
| COEP Stock | USD 0.20 0.01 5.26% |
Our overall analysis of Coeptis Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Coeptis Therapeutics. The specific impact of Coeptis Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Coeptis Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Coeptis Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Coeptis Therapeutics Backtesting and Coeptis Therapeutics Hype Analysis. To learn how to invest in Coeptis Stock, please use our How to Invest in Coeptis Therapeutics guide.
Coeptis |
Coeptis Therapeutics Today Top News and Investor Outlook
Coeptis Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Coeptis and other traded companies coverage with news coverage. We help investors stay connected with Coeptis headlines for the 30th of November to make an informed investment decision based on correlating the impacts of news items on Coeptis Stock performance. Please note that trading solely based on the Coeptis Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Coeptis Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Coeptis earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Coeptis Therapeutics that are available to investors today. That information is available publicly through Coeptis media outlets and privately through word of mouth or via Coeptis internal channels. However, regardless of the origin, that massive amount of Coeptis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Coeptis Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Coeptis Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Coeptis Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Coeptis Therapeutics alpha.
Coeptis Largest EPS Surprises
Earnings surprises can significantly impact Coeptis Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-28 | 2024-06-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2023-08-11 | 2023-06-30 | -0.2 | -0.1427 | 0.0573 | 28 | ||
2023-05-15 | 2023-03-31 | -0.28 | -0.39 | -0.11 | 39 | ||
2023-11-09 | 2023-09-30 | -0.01 | -0.23 | -0.22 | 2200 | ||
2023-03-29 | 2022-12-31 | -0.08 | -2.59 | -2.51 | 3137 |
Coeptis Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Coeptis Therapeutics Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
26th of November 2024
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Program... at businesswire.com
25th of November 2024
Acquisition by Lawrence Bryan Jay of 5000 shares of Cingulate at 1.18 subject to Rule 16b-... at MacroaxisInsider
22nd of November 2024
Agricultural Biotechnology Market to Evolve at an Impressive 8.8 percent CAGR through 2031... at globenewswire.com
22nd of November 2024
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility... at globenewswire.com
20th of November 2024
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nin... at news.google.com
20th of November 2024
Warning REVB is at high risk of performing badly - MSN at news.google.com
20th of November 2024
Down -35.74 percent in 4 Weeks, Heres Why PDS Biotechnology Looks Ripe for a Turnaround at zacks.com
19th of November 2024
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors at finance.yahoo.com
18th of November 2024
Dyadic International, Inc. Q3 2024 Earnings Call Transcript at insidermonkey.com
18th of November 2024
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corpo... at gurufocus.com
18th of November 2024
Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings at investing.com
15th of November 2024
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeutics Inc at gurufocus.com
15th of November 2024
Genelux GAAP EPS of -0.19 beats by 0.01 at seekingalpha.com
14th of November 2024
MPM BioImpact Appoints Michael Ehlers, M.D., Ph.D., Experienced RD Leader and Accomplished... at finance.yahoo.com
14th of November 2024
Dyadic shares retain buy rating on positive analyst outlook, revenue growth at investing.com
14th of November 2024
ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com at news.google.com
12th of November 2024
Sonnet BioTherapeutics Releases Virtual Investor What this Means Segment at globenewswire.com
12th of November 2024
Acquisition by Buckland Barry of 11793 shares of Dyadic International at 1.59 subject to R... at gurufocus.com
11th of November 2024
Monopar Therapeutics stock target lifted, buy rating on AstraZeneca deal at investing.com
8th of November 2024
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months End... at businesswire.com
8th of November 2024
ALLR Deadline ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securiti... at prnewswire.com
7th of November 2024
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Acce... at finance.yahoo.com
7th of November 2024
Cingulate Reports Third Quarter 2024 Financial ResultsReflecting 19.5 Million Increase in ... at finance.yahoo.com
6th of November 2024
Sonnet BioTherapeutics Announces Pricing of 5.0 Million Underwritten Public Offering Price... at finance.yahoo.com
5th of November 2024
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome... at finance.yahoo.com
4th of November 2024
Zoetis Q3 Earnings and Revenues Beat Estimates at zacks.com
31st of October 2024
While institutions invested in Genelux Corporation benefited from last weeks 34 percent ga... at simplywall.st
29th of October 2024
The Schall Law Firm Invites Stockholders To Join A Lawsuit Against Allarity Therapeutics, ... at accesswire.com
28th of October 2024
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock at globenewswire.com
25th of October 2024
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medic... at globenewswire.com
24th of October 2024
Monopar Therapeutics Shares Surge on Partnership with Alexion at gurufocus.com
21st of October 2024
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra... at businesswire.com
10th of October 2024
Aditxts Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders... at finance.yahoo.com
8th of October 2024
Virios Therapeutics Soars Over 33 percent on Merger Announcement at gurufocus.com
8th of October 2024
INVESTOR DEADLINE APPROACHING Faruqi Faruqi, LLP Investigates Claims on Behalf of Investor... at news.google.com
7th of October 2024
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflamm... at globenewswire.com
3rd of October 2024
Acquisition by Cogley Brian of 5000 shares of Coeptis Therapeutics at 0.67 subject to Rule... at MacroaxisInsider
2nd of October 2024
Acquisition by Thomas John of 2500 shares of Genelux Common at 5.25 subject to Rule 16b-3 at MacroaxisInsider
1st of October 2024
Virios Therapeutics stock hits 52-week low at 0.15 - Investing.com at news.google.com
26th of September 2024
Longeveron to Attend Alliance for Regenerative Medicines Cell Gene Meeting on the Mesa - S... at news.google.com
24th of September 2024
Revelation Biosciences Gemini Induces Dose Dependent Significant Increases in IL-10 at finance.yahoo.com
23rd of September 2024
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioproces... at globenewswire.com
19th of September 2024
Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Cont... at finance.yahoo.com
16th of September 2024
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneer... at globenewswire.com
13th of September 2024
Discretionary transaction by Striar Robert of tradable shares of Coeptis Therapeutics subj... at Striar Robert
6th of September 2024
Discretionary transaction by Calise Chris of tradable shares of Coeptis Therapeutics subje... at Calise Chris
5th of September 2024
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategi... at finance.yahoo.com
5th of September 2024
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utili... at finance.yahoo.com
13th of August 2024
VIRI Enrollment Complete in Phase 2a Long COVID Trial Results Expected in October 2024 at finance.yahoo.com
8th of August 2024
VIRI Stock Earnings Virios Therapeutics Beats EPS for Q2 2024 at investorplace.com
24th of May 2024
YS Biopharma to change legal name to LakeShore Biopharma at seekingalpha.com
10th of July 2023
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2HER... at news.google.com
30th of June 2023
Kiromic Biopharma Shares Down 12 percent After Stock Offering Prospectus at marketwatch.com
18th of May 2023
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates MGTA, CHRA, STSA at hawaiinewsnow.com
16th of May 2023
Should You Hold Kiromic Biopharma Inc Stock Tuesday Morning - InvestorsObserver at news.google.com
3rd of May 2023
Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death at finance.yahoo.com
3rd of May 2023
Kiromic BioPharma, Inc. Sees Large Increase in Short Interest at thelincolnianonline.com
27th of April 2023
Hillstream BioPharma, Inc. Short Interest Update at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Coeptis Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Coeptis Therapeutics' short interest history, or implied volatility extrapolated from Coeptis Therapeutics options trading.
Additional Tools for Coeptis Stock Analysis
When running Coeptis Therapeutics' price analysis, check to measure Coeptis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coeptis Therapeutics is operating at the current time. Most of Coeptis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Coeptis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coeptis Therapeutics' price. Additionally, you may evaluate how the addition of Coeptis Therapeutics to your portfolios can decrease your overall portfolio volatility.